Psychiatry/Behavioral · PANCE / PANRE

Panic Disorder

Recurrent unexpected panic attacks plus >=1 month of worry about future attacks or maladaptive behavior change.

Also known as: panic attacks, panic disorder, agoraphobia

Overview

Recurrent, unexpected panic attacks — abrupt surges of intense fear or discomfort peaking within minutes — followed by >=1 month of persistent concern about additional attacks, worry about their consequences, or significant maladaptive behavior change.

Epidemiology

Lifetime prevalence ~3-5%. Female-to-male ratio ~2:1. Bimodal onset: late adolescence/early adulthood and mid-30s. ~30-50% develop agoraphobia.

Try two board-style Panic Disorder questions

Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.

Question 1PsychiatryMedium
A 28-year-old man has recurrent, unexpected episodes of sudden palpitations, sweating, trembling, shortness of breath, and fear of dying that peak within minutes. For the past 3 months he has worried persistently about having further episodes and now avoids buses, stores, and other crowded public places because escape might be difficult. Which of the following is the most likely diagnosis?
  • ASpecific phobia, situational type
  • BPanic disorder and agoraphobia
  • CSocial anxiety disorder
  • DGeneralized anxiety disorder
Reveal answer & full explanation
Correct answer: B — Panic disorder and agoraphobia
  • ASpecific phobia, situational type
  • BPanic disorder and agoraphobia
  • CSocial anxiety disorder
  • DGeneralized anxiety disorder

Why Panic disorder and agoraphobia is correct

  • Recurrent, unexpected attacks of palpitations, sweating, trembling, dyspnea, and fear of dying peaking within minutes are panic attacks; with ≥1 month of persistent concern about further attacks, this defines panic disorder
  • Avoidance of buses, stores, and crowds because escape might be difficult is agoraphobic avoidance, present here for 3 months; DSM-5-TR codes panic disorder and agoraphobia as two separate, comorbid diagnoses
  • Treatment is a selective serotonin reuptake inhibitor (SSRI) — paroxetine, sertraline, and fluoxetine are FDA approved for panic disorder — combined with cognitive behavioral therapy (CBT) using interoceptive (body sensation) and situational (phobic avoidance) exposure
  • Benzodiazepines are short-term only; they risk dependence and interfere with CBT fear extinction

Why the others are wrong

  • Specific phobia, situational type — fear is cued by one specific situation (e.g., flying, enclosed spaces) and attacks are expected on exposure; here the initial attacks were unexpected and avoidance spans many settings (confused-with-agoraphobia trap)
  • Social anxiety disorder — fear centers on social scrutiny or embarrassment; this patient avoids places because escape would be difficult, not because of being judged (buzzword-matching 'avoids public places')
  • Generalized anxiety disorder — excessive worry across multiple life domains for ≥6 months without discrete unexpected attacks; choosing it anchors on 'worried persistently' while ignoring the episodic attack pattern
Question 2PsychiatryMedium
A 45-year-old male has had panic attacks for 2 years — sudden episodes of intense fear, palpitations, shortness of breath, dizziness, chest tightness, and fear of dying lasting 10-15 minutes. He now avoids driving, crowded places, and situations where he cannot escape, significantly limiting his work and social life. Which of the following is the most likely diagnosis?
  • ASocial anxiety disorder (social phobia)
  • BGeneralized anxiety disorder
  • CPanic disorder and agoraphobia
  • DSpecific phobia, situational type
Reveal answer & full explanation
Correct answer: C — Panic disorder and agoraphobia
  • ASocial anxiety disorder (social phobia)
  • BGeneralized anxiety disorder
  • CPanic disorder and agoraphobia
  • DSpecific phobia, situational type

Why Panic disorder and agoraphobia is correct

  • Panic disorder = recurrent unexpected panic attacks PLUS at least 1 month of persistent concern about future attacks OR maladaptive avoidance behavior — both are present here
  • Agoraphobia = marked fear or avoidance of two or more situations where escape might be difficult or help unavailable (crowds, driving, bridges, enclosed spaces, public transportation) — matches this patient's avoidance of driving and crowded places
  • DSM-5 codes panic disorder and agoraphobia as two separate, independently co-codable diagnoses rather than a single combined entity, so both are named when they coexist
  • The 2-year course with functional impairment of work and social life confirms clinically significant, persistent disease

Why the others are wrong

  • Social anxiety disorder (social phobia) — fear and avoidance are confined to social or performance situations involving scrutiny by others, not to any setting where escape is difficult (right-concept-wrong-trigger)
  • Generalized anxiety disorder — excessive worry across multiple life domains for at least 6 months without discrete panic attacks or agoraphobic avoidance (confused-with a chronic-worry picture)
  • Specific phobia, situational type — fear is limited to one circumscribed stimulus and is not driven by fear of a panic attack; this patient's avoidance is broad and panic-linked (anchoring on the situational overlap)

Additional high-yield points

  • First-line treatment: (1) Cognitive behavioral therapy (CBT) with interoceptive exposure (intentionally inducing feared bodily sensations to reduce fear), cognitive restructuring (correcting catastrophic misinterpretation of normal sensations), and gradual in-vivo exposure for agoraphobia; (2) Selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) (sertraline, paroxetine, escitalopram, venlafaxine) — onset 4–8 weeks; treat for minimum 12 months after remission; (3) Combined CBT plus medication is superior for severe or treatment-resistant cases
  • Benzodiazepines: short-term bridge only — risk of dependence, tolerance, rebound anxiety, and blunting of CBT exposure benefit
  • D-cycloserine: NMDA partial agonist as adjunct to CBT (investigational)
🔒 Free preview limit reached

Keep reading — start your free trial

You've read your 2 free diagnosis previews. Create your free account to unlock the full Panic Disorder outline — plus all 514 diagnoses, 6,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.

Free to start · No credit card · Cancel anytime

Risk factors

  • Female sex, family history of panic or anxiety disorders
  • Smoking, asthma, mitral valve prolapse (modest association)
  • Childhood adversity, recent stressful life events
  • Caffeine and stimulant use, cannabis

Pathophysiology

Hypersensitive 'fear network' centered on the amygdala with augmented locus coeruleus noradrenergic output; abnormal CO2/lactate sensitivity producing 'false suffocation alarms.' Genetic heritability ~40%.

Clinical presentation

Symptoms

  • Panic attack: >=4 of 13 symptoms peaking within minutes — palpitations, sweating, trembling, dyspnea, choking sensation, chest pain, nausea, dizziness, chills/heat, paresthesias, derealization/depersonalization, fear of losing control, fear of dying
  • Attacks last 10-30 minutes; afterwards, patients feel exhausted
  • Anticipatory anxiety between attacks and avoidance of perceived triggers
  • Agoraphobia: fear/avoidance of >=2 of: public transportation, open spaces, enclosed spaces, lines/crowds, being outside the home alone

Signs / physical exam

  • During attack: tachycardia, tachypnea, diaphoresis, mild HTN, tremor, hyperventilation
  • Between attacks: typically normal exam

Differential diagnosis

  • Cardiac (ACS, arrhythmia, SVT) — Exertional trigger, abnormal ECG/troponin, persistent symptoms — must exclude in first presentations
  • Pulmonary embolism — Hypoxia, tachycardia, pleuritic pain, risk factors; D-dimer, CTPA
  • Hyperthyroidism / pheochromocytoma — Sustained tachycardia, weight loss, paroxysmal HTN, suppressed TSH or elevated metanephrines
  • Hypoglycemia — Diaphoresis, tremor, confusion; documented low glucose
  • Vestibular dysfunction — Vertigo with positional change; nystagmus on exam
  • Substance intoxication/withdrawal — Cocaine, methamphetamine, cannabis, alcohol/benzo withdrawal
  • GAD — Chronic worry without discrete attacks
  • PTSD — Trauma cue triggers; intrusive memories

Diagnostic workup

Diagnostic criteria

DSM-5-TR: Recurrent unexpected panic attacks AND >=1 month of one or both: (a) persistent concern about additional attacks or their consequences, (b) significant maladaptive change in behavior related to attacks. Not attributable to substance/medical condition and not better explained by another disorder. Agoraphobia is a separate, often co-occurring diagnosis.

Labs

  • Targeted to exclude medical mimics: ECG, troponin (if cardiac risk), TSH, BMP, glucose, urine drug screen, urine metanephrines (paroxysmal HTN)

Imaging

  • Not routinely required; CT/CTA only if PE, dissection, or other organic cause suspected

Diagnostic algorithm

flowchart TD
  A[Recurrent abrupt fear surges<br/>peak <10 min] --> B[Exclude medical mimics<br/>ECG / TSH / glucose / UDS]
  B --> C{>=4 panic symptoms?}
  C -->|Yes| D[Panic attack]
  D --> E{>=1 month worry<br/>or behavior change?}
  E -->|Yes| F[Panic Disorder]
  E -->|No| G[Isolated panic attacks]
  F --> H[CBT with exposure +/- SSRI/SNRI]
  F --> I[Short-term benzo bridge<br/>if severe]
Panic disorder diagnostic and treatment algorithm.

Treatment

First-line

  • Cognitive behavioral therapy with interoceptive and in vivo exposure — strongest evidence base
  • SSRI — sertraline, escitalopram, paroxetine, fluoxetine (start at low dose to avoid initial activation)
  • SNRI — venlafaxine XR
  • Patient education: panic attacks are time-limited, not dangerous; reduce safety behaviors

Second-line / adjunct

  • Benzodiazepine (clonazepam, lorazepam, alprazolam) — short-term bridge for severe early symptoms; avoid as long-term monotherapy due to dependence and rebound anxiety; absolutely avoid in SUD
  • Tricyclic antidepressants (imipramine, clomipramine) — effective but anticholinergic and overdose-toxic
  • MAOIs reserved for refractory cases
  • Adjunctive lifestyle: limit caffeine/stimulants, cardiovascular exercise, sleep regularization

Complications

  • Agoraphobia and functional restriction
  • Comorbid depression, GAD, alcohol/sedative misuse
  • Suicide risk increased relative to non-anxious controls
  • Repeated ED visits and unnecessary cardiac workups

PANCE pearls

  • Panic attacks peaking >10 minutes or with focal neurologic signs are atypical — broaden the differential.
  • Alprazolam has the highest dependence and rebound risk; if benzodiazepines are used, clonazepam (longer half-life) is preferred.
  • Cognitive model: catastrophic misinterpretation of benign bodily sensations drives the panic cycle — interoceptive exposure breaks the association.
  • Continue SSRI for >=12 months after remission to reduce relapse.

References

  • APA 2009 — American Psychiatric Association Practice Guideline for the Treatment of Patients with Panic Disorder, 2nd ed. (2009)
  • NICE CG113 — NICE Clinical Guideline 113: Generalised anxiety disorder and panic disorder in adults
  • DSM-5-TR — American Psychiatric Association. DSM-5-TR (2022)

Practice Psychiatry/Behavioral questions on FirstPassPA

Turn this outline into retention. 6,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Answer the 2 free questions above → Get today's free question →

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.